Severity of inflammatory syndrome and endothelial dysfunction in steatosis and liver fibrosis

Abstract

Objective. To evaluate the severity of the inflammatory syndrome by the serum concentration of proinflammatory cytokines of tumor necrosis factor alpha (TNF-α) and interleukin-6, endothelial dysfunction syndrome (ED) by the level of vasculoendothelial growth factor (VEGF) and the functional activity of Willebrand factor (WF) in the blood of patients with nonalcoholic liver steatosis (NALS) and liver fibrosis (LF) of viral genesis.

Materials and methods. 52 patients with NALS and 27 patients with LF of viral etiology (hepatitis C) were examined. The control group included 20 practically healthy individuals. The concentrations of TNF-α, IL-6 and VEGF were determined in the blood by enzyme immunoassay. The functional activity of WF was measured by the level of aggregation with the inducer ristocetin using laser aggregometer.

Results. According to the results of ELISA, an increase in serum levels of proinflammatory cytokines TNF-α and IL-6 was registered in patients of both study groups in comparison with the control, being more pronounced in patients with viral LF. Hyperproduction of VEGF was observed in both groups of patients, and the concentration of this marker was significantly higher in viral LF than in patients with NALS (p = 0.002). The functional activity of WF in patients with NALS and in the group with LF also significantly exceeded the control values, but there were no significant differences between the nosological forms (p = 0.675).

Conclusions. The course of NALS and viral LF is characterized by the development of an inflammatory syndrome and ED, associated with an increase in the production of proinflammatory cytokines TNF-α and IL-6 and hyperproduction of VEGF, more pronounced in LF. The functional activity of WF also increases in both nosological forms, but without significant differences.

Keywords

nonalcoholic liver steatosis / liver fibrosis / cytokines / endothelial dysfunction

References

[1] Morozova T.S., Grishina I.F., Kovtun O.P. Cytokine profile in chronic diffuse liver diseases (literature review). Ural'skiy meditsinskiy zhurnal 2018; 13 (168): 119–134 (in Russian).

[2] Морозова Т.С., Гришина И.Ф., Ковтун О.П. Цитокиновый профиль при хронических диффузных заболеваниях печени (обзор литературы). Уральский медицинский журнал 2018; 13 (168): 119–134.

[3] Bueverov A.O., Bogomolov P.O. "Cytokine explosion" and the progression of non-alcoholic steatohepatitis. Klinicheskie perspektivy gastroenterologii, gepatologii 2012; 5: 12–18 (in Russian).

[4] Буеверов А.О., Богомолов П.О. «Цитокиновый взрыв» и прогрессирование неалкогольного стеатогепатит. Клинические перспективы гастроэнтерологии, гепатологии 2012; 5: 12–18.

[5] Ivashkin V.T., Maevskaya M.V., Pavlov Ch.S. i dr. Clinical recommendations for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroenterologii, gepatologii i koloproktologii 2016; 2: 24–42 (in Russian).

[6] Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии и колопроктологии 2016; 2: 24–42.

[7] Mekhtiev S. N., Stepanenko V.V., Zinov'eva E.N., Mekhtieva O.A. Modern ideas about liver fibrosis and methods of its correction. Farmateka 2014; 6: 80–87 (in Russian).

[8] Мехтиев С.Н., Степаненко В.В., Зиновьева Е.Н., Мехтиева О.А. Со-временные представления о фиброзе печени и методах его коррекции. Фарматека 2014; 6: 80–87.

[9] Chistyakova M.V., Govorin A.V., Radaeva E.V. Functional state of the endothelium in patients with viral hepatitis and cirrhosis of the liver. Kazanskiy meditsinskiy zhurnal 2014; 1 (95): 41–45 (in Russian).

[10] Чистякова М.В., Говорин А.В., Радаева Е.В. Функциональное состояние эндотелия у пациентов с вирусным гепатитом и циррозом печени. Казанский медицинский журнал 2014; 1 (95): 41–45.

[11] Yang L., Kwon J., Popov Y., Gajdos G.B., Ordog T., Brekken R.A., Mukhopadhyay D., Schuppan D., Bi Y., Simonetto D., Shah V.H. Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice. Gastroenterology 2014; 5 (146): 1339–1350.

[12] Drapkina O.M., Deeva T.A., Ivashkin V.T. Evaluation of endothelial function and the degree of apoptosis in patients with metabolic syndrome and non-alcoholic fatty liver disease. Terapevticheskiy arkhiv 2015; 5 (87): 76–83 (in Russian).

[13] Драпкина О.М., Деева Т.А., Ивашкин В.Т. Оценка эндотелиальной функции и степени апоптоза у пациентов с метаболическим синдромом и неалкогольной жировой болезнью печени. Терапевтический архив 2015; 5 (87): 76–83.

[14] Shelud'ko V.S., Devyatkova G.I. Theoretical foundations of medical statistics (statistical methods of processing and analysis of research materials: ucheb.-metod. posobie. Izd 3-e, ispravl. i dop. Perm': FGBOU VO PGMU im. akademika E.A. Vagnera Minzdrava Rossii; Saratov: Amirit 2019; 96 (in Russian).

[15] Шелудько В.С., Девяткова Г.И. Теоретические основы медицинской статистики (статистические методы обработки и анализа материалов научно-исследовательских работ: учеб.-метод. пособие. 3-е изд., испр. и доп. Пермь: ФГБОУ ВО ПГМУ им. академика Е.А. Вагнера Минздрава России; Саратов: Амирит 2019; 96.

[16] Geyvandova N.I., Belova N.G., Aleksandrovich G.A. Serum cytokines in patients with non-alcoholic fatty liver disease and their relationship with the severity of morphological changes. Meditsinskiy vestnik Severnogo Kavkaza 2011; 1: 9–12 (in Russian).

[17] Гейвандова Н.И., Белова Н.Г., Александрович Г.А. Сывороточные цитокины у больных неалкогольной жировой болезнью печени и их взаимосвязь с выраженностью морфологических изменений. Медицинский вестник Северного Кавказа 2011; 1: 9–12.

[18] Aldasheva Zh.A., Salkhanov B.A., Davlyatshin T.I., Ayupova Zh.G. Evaluation of the diagnostic value of the determination of certain cytokines in the blood serum of patients with liver steatosis. Vestnik AGIUV 2010; 2: 26–28 (in Russian).

[19] Алдашева Ж.А., Салханов Б.А., Давлятшин Т.И., Аюпова Ж.Г. Оценка диагностической ценности определения некоторых цитокинов в сыворотке крови больных со стеатозами печени. Вестник АГИУВ 2010; 2: 26–28.

[20] Zhang Y., Chatzistamou I., Kiaris H. Transcriptomic coordination at hepatic steatosis indicates robust immune cell engagement prior to inflammation. BMC Genomics 2021; 22 (1): 454.

[21] Korotchaeva Yu.V., Samokhodskaya L.M., Speranskiy A.I. i dr. Prognostic value of determination of Il-6 in blood serum and cytochrome P450 in liver tissue in patients with chronic hepatitis C. Rossiyskiy zhurnal gastroenterologii, gepatologii, kolopraktologii 2008; 2 (18): 42–47 (in Russian).

[22] Коротчаева Ю.В., Самоходская Л.М., Сперанский А.И. и др. Прогностическое значение определения Ил-6 в сыворотке крови и цитохрома Р450 в ткани печени у больных хроническим гепатитом С. Российский журнал гастроэнтерологии, гепатологии, колопрактологии 2008; 2 (18): 42–47.

[23] Daniela Adriana Ion., Mihaela Radulescu, Victoria Aramă et al. Inflammatory patterns in patients with chronic hepatitis C. BMC Infectious Diseases 2013; 13 (suppl 1).

[24] Daniela Adriana Ion., Mihaela Rad-ulescu, Victoria Aramă et al. Inflammatory patterns in patients with chronic hepatitis C. BMC Infectious Diseases 2013; 13 (suppl 1).

[25] Hammam О., Mahmoud О., Zahran М. et al. A Possible Role for TNF-α in Coordinating Inflammation and Angiogenesis in Chronic Liver Disease and Hepatocellular Carcinoma. Gastrointest. Cancer Res 2013; 4 (6):107–114.

[26] Hammam О., Mahmoud О., Zahran М. et al. A Possible Role for TNF-α in Coordinating Inflammation and Angio-genesis in Chronic Liver Disease and Hepatocellular Carcinoma. Gastrointest. Cancer Res 2013; 4 (6): 107–114.

[27] Jarrar М.Н., Baranova А., Collantes R. et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 5 (27): 412–421.

[28] Bilgir О., Bilgir F., Bozkaya G., Calan М. Changes in the levels of endotheliumderived coagulation parameters in nonalcoholic fatty liver disease. Blood Coagul Fibrinolysis 2014; 2 (25): 151–155.

[29] Bilgir О., Bilgir F., Bozkaya G., Calan М. Changes in the levels of endotheliumderived coagulation parameters in nonalcoholic fatty liver disease. Blood Coagul. Fibrinolysis 2014; 2 (25): 151–155.

[30] Verrijken А., Francque S., Mertens I. et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2014; 1 (59): 121–129.

[31] Targher G., Byrne C.D. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin Thromb Hemost 2013; 2 (39): 214–228.

[32] Pivtorak E.V. Endothelial dysfunction in patients with non-alcoholic fatty liver disease. Eksperimental'naya i klinicheskaya gastroenterologiya 2014; 2 (102): 63 (in Russian).

[33] Пивторак Е.В. Нарушения функции эндотелия у больных неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология 2014; 2 (102): 63.

[34] Vul'f M.A., Kirienkova E.V., Skuratovskaya D.A., Levada E.V., Volkova L.V., Zatolokin P.A., Gazatova N.D., Litvinova L.S. Factors contributing to the development of non-alcoholic fatty liver disease and insulin resistance in obesity. Biomeditsinskaya khimiya 2018; 64 (5): 444–450 (in Russian).

[35] Вульф М.А., Кириенкова Е.В., Скуратовская Д.А., Левада E.В., Волкова Л.В., Затолокин П.А., Газатова Н.Д., Литвинова Л.С. Факторы, способствующие развитию неалкогольной жировой болезни печени и инсулинорезистентности при ожирении. Биомедицинская химия 2018; 64 (5): 444–450.

RIGHTS & PERMISSIONS

Bulatova I.A., Miftakhova A.M., Gulyaeva I.L.